Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.43 |
| ▸ | NPC1L1 | Q9UHC9 | 12/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318533 | 0.96 | OPRM1 (0.46) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL318532 | 0.96 | OPRM1 (0.46) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL318548 | 0.96 | OPRM1 (0.46) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL9998873 | 0.91 | OPRM1 (0.42) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL318508 | 0.85 | OPRK1 (0.42) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL319429 | 0.85 | OPRK1 (0.42) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL318507 | 0.85 | OPRK1 (0.42) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL318086 | 0.85 | OPRL1 (0.48) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL318087 | 0.85 | OPRL1 (0.48) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL318391 | 0.85 | OPRL1 (0.48) | OPRM1OPRD1OPRK1OPRL1NPC1L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | OPRM1 92/4885OPRD1 12/4885OPRK1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.